Literature DB >> 22727550

Treatment of left sided breast cancer for a patient with funnel chest: volumetric-modulated arc therapy vs. 3D-CRT and intensity-modulated radiotherapy.

Petra M Haertl1, Fabian Pohl, Karin Weidner, Christian Groeger, Oliver Koelbl, Barbara Dobler.   

Abstract

This case study presents a rare case of left-sided breast cancer in a patient with funnel chest, which is a technical challenge for radiation therapy planning. To identify the best treatment technique for this case, 3 techniques were compared: conventional tangential fields (3D conformal radiotherapy [3D-CRT]), intensity-modulated radiotherapy (IMRT), and volumetric-modulated arc therapy (VMAT). The plans were created for a SynergyS® (Elekta, Ltd, Crawley, UK) linear accelerator with a BeamModulator™ head and 6-MV photons. The planning system was Oncentra Masterplan® v3.3 SP1 (Nucletron BV, Veenendal, Netherlands). Calculations were performed with collapsed cone algorithm. Dose prescription was 50.4 Gy to the average of the planning target volume (PTV). PTV coverage and homogeneity was comparable for all techniques. VMAT allowed reducing dose to the ipsilateral organs at risk (OAR) and the contralateral breast compared with IMRT and 3D-CRT: The volume of the left lung receiving 20 Gy was 19.3% for VMAT, 26.1% for IMRT, and 32.4% for 3D-CRT. In the heart, a D(15%) of 9.7 Gy could be achieved with VMAT compared with 14 Gy for IMRT and 46 Gy for 3D-CRT. In the contralateral breast, D(15%) was 6.4 Gy for VMAT, 8.8 Gy for IMRT, and 10.2 Gy for 3D-CRT. In the contralateral lung, however, the lowest dose was achieved with 3D-CRT with D(10%) of 1.7 Gy for 3D-CRT, and 6.7 Gy for both IMRT and VMAT. The lowest number of monitor units (MU) per 1.8-Gy fraction was required by 3D-CRT (192 MU) followed by VMAT (518 MU) and IMRT (727 MU). Treatment time was similar for 3D-CRT (3 min) and VMAT (4 min) but substantially increased for IMRT (13 min). VMAT is considered the best treatment option for the presented case of a patient with funnel chest. It allows reducing dose in most OAR without compromising target coverage, keeping delivery time well below 5 minutes.
Copyright © 2013 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22727550     DOI: 10.1016/j.meddos.2012.04.003

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  5 in total

1.  Helical tomotherapy and volumetric modulated arc therapy: New therapeutic arms in the breast cancer radiotherapy.

Authors:  Olivier Lauche; Youlia M Kirova; Pascal Fenoglietto; Emilie Costa; Claire Lemanski; Celine Bourgier; Olivier Riou; David Tiberi; Francois Campana; Alain Fourquet; David Azria
Journal:  World J Radiol       Date:  2016-08-28

2.  Secondary cancer risk after whole-breast radiation therapy: field-in-field versus intensity modulated radiation therapy versus volumetric modulated arc therapy.

Authors:  Emel Haciislamoglu; Yunus Cinar; Fatih Gurcan; Emine Canyilmaz; Gorkem Gungor; Adnan Yoney
Journal:  Br J Radiol       Date:  2019-07-22       Impact factor: 3.039

3.  The Role of Adjuvant Radiotherapy for a Case of Primary Breast Sarcoma: A Plan Comparison between Three Modern Techniques and a Review of the Literature.

Authors:  Mariella Cozzolino; Caterina Oliviero; Barbara D'Andrea; Giuseppe Guglielmi; Giorgia Califano; Rocchina Caivano; Antonella Bianculli; Vincenzo Fusco
Journal:  Case Rep Med       Date:  2018-04-17

4.  Simultaneous integrated boost (SIB) radiation therapy of right sided breast cancer with and without flattening filter - A treatment planning study.

Authors:  Johannes Maier; Bernadette Knott; Manuel Maerz; Rainer Loeschel; Oliver Koelbl; Barbara Dobler
Journal:  Radiat Oncol       Date:  2016-08-31       Impact factor: 3.481

5.  Calculated relative biological effectiveness (RBE) for initial DNA double-strand breaks (DSB) from flattening filter and flattening filter-free 6 MV X-ray fields.

Authors:  Hisashi Nakano; Daisuke Kawahara; Satoshi Tanabe; Satoru Utsunomiya; Takeshi Takizawa; Madoka Sakai; Toshimichi Nakano; Atsushi Ohta; Motoki Kaidu; Hiroyuki Ishikawa
Journal:  BJR Open       Date:  2021-07-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.